Insulet Corp (PODD) stock
PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 21/3046% below fair value
$150.03+1.97 (+1.33%)
Close on Nov 11, 2026Market cap $10.41BP/E 24.4Yield –
Insulet EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Insulet's EPS for the twelve months ending Sep 30, 2026 was $6.14, up 79.5% year over year. For fiscal 2025 it was $3.48, down 39.8% from the year before. The highest annual figure on record is $5.78 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.48 | -39.8% |
| FY2024 | Dec 31, 2024 | $5.78 | +96.6% |
| FY2023 | Dec 31, 2023 | $2.94 | +4100.0% |
| FY2022 | Dec 31, 2022 | $0.07 | -70.8% |
| FY2021 | Dec 31, 2021 | $0.24 | +140.0% |
| FY2020 | Dec 31, 2020 | $0.10 | -47.4% |
| FY2019 | Dec 31, 2019 | $0.19 | +280.0% |
| FY2018 | Dec 31, 2018 | $0.05 | – |
| FY2017 | Dec 31, 2017 | -$0.46 | – |
| FY2016 | Dec 31, 2016 | -$0.48 | – |
| FY2015 | Dec 31, 2015 | -$1.29 | – |
| FY2014 | Dec 31, 2014 | -$0.93 | – |
| FY2013 | Dec 31, 2013 | -$0.83 | – |
| FY2012 | Dec 31, 2012 | -$1.08 | – |
| FY2011 | Dec 31, 2011 | -$0.98 | – |
| FY2010 | Dec 31, 2010 | -$1.54 | – |
| FY2009 | Dec 31, 2009 | -$2.43 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.03 | +63.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.37 | +328.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.30 | +160.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.44 | +5.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.24 | +14.8% |
| Q2 FY2025 | Jun 30, 2025 | $0.32 | -87.6% |
| Q1 FY2025 | Mar 31, 2025 | $0.50 | -31.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.36 | +10.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.08 | +45.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.59 | +564.1% |
| Q1 FY2024 | Mar 31, 2024 | $0.73 | +114.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.23 | +412.5% |
| Q3 FY2023 | Sep 30, 2023 | $0.74 | – |
| Q2 FY2023 | Jun 30, 2023 | $0.39 | – |
| Q1 FY2023 | Mar 31, 2023 | $0.34 | -15.0% |
| Q4 FY2022 | Dec 31, 2022 | $0.24 | -40.0% |
| Q3 FY2022 | Sep 30, 2022 | -$0.08 | -144.4% |
| Q2 FY2022 | Jun 30, 2022 | -$0.50 | – |
| Q1 FY2022 | Mar 31, 2022 | $0.40 | – |
| Q4 FY2021 | Dec 31, 2021 | $0.40 | – |
| Q3 FY2021 | Sep 30, 2021 | $0.18 | +5.9% |
| Q2 FY2021 | Jun 30, 2021 | -$0.37 | -268.2% |
| Q1 FY2021 | Mar 31, 2021 | $0.00 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.26 | -425.0% |
| Q3 FY2020 | Sep 30, 2020 | $0.17 | +1600.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.22 | +1000.0% |
| Q1 FY2020 | Mar 31, 2020 | -$0.03 | -142.9% |
| Q4 FY2019 | Dec 31, 2019 | $0.08 | -50.0% |
| Q3 FY2019 | Sep 30, 2019 | $0.01 | -66.7% |
| Q2 FY2019 | Jun 30, 2019 | $0.02 | – |
| Q1 FY2019 | Mar 31, 2019 | $0.07 | – |
| Q4 FY2018 | Dec 31, 2018 | $0.16 | – |
| Q3 FY2018 | Sep 30, 2018 | $0.03 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.03 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.11 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.12 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.04 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.13 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.17 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.16 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?